You are here

The Progress Report Progress never stops. Stay informed with the latest news on breast cancer research, treatment, and prevention.


triple-negative breast cancer x

a younger woman stands in front of her doctor to prepare for a breast exam, their faces aren't shown

To talk about triple-negative breast cancer (often shortened to TNBC), we must first understand how breast cancer is classified.

portrait of mackenzie smiling and looking at the camera

A month into dating, Mackenzie Dougherty, 35, decided to tell her new boyfriend, David, that she carried the BRCA1 gene mutation.

“But I didn’t expect we would have to fight breast cancer together anytime soon,” she said.

patient and doctor holding hands

Triple-negative breast cancer (TNBC) gets its name from the fact that it is not driven by breast cancer’s three major molecular markers—estrogen receptor, progesterone receptor, and the HER2 oncogene—that classify breast cancer subtypes, making it untreatable with hormone- or HER2-directed therap

Doctor wearing a lab coat and mask holding a clip board speaks to a patient

At this year’s virtual San Antonio Breast Cancer Symposium (SABCS)—the world’s largest scientific conference dedicated to breast cancer—investigators reported a number of key findings from trials testing immunotherapies and targeted agents for triple-negative breast cancer (TNBC), an aggressive f

Portrait of Alicia and her daughter smiling

A month before her 40th birthday, Alicia Therien went in for her yearly gynecologic exam, thinking she’d start getting an annual mammogram. She’d had one two years prior after feeling several lumps in her breasts following her son’s birth.

Lab worker with samples

Triple-negative breast cancer (TNBC) is very aggressive and fast-growing, with nearly no targeted therapies available today. TNBC represents 10 to 20 percent of diagnosed breast cancers and is more likely to affect younger people and those with a BRCA1 gene mutation.

To understand triple-negative breast cancer, we first have to understand how breast cancer is classified. Breast tumors are broadly classified into three major subtypes: estrogen receptor (ER)- and/or progesterone receptor (PR)-positive, HER2 receptor positive, or triple-negative.

Immunotherapy Extends Lives for Patients with Advanced Triple Negative Breast Cancer

Triple-negative breast cancer is an aggressive disease with a high likelihood of spreading to other tissues, a process called metastasis. TNBC is primarily treated with chemotherapy.